Skip to main content
F
Formulate
Jobs
Companies
Drugs
Advisor
NEW
Insider Intel
Salary
Pricing
Toggle theme
Toggle theme
Menu
argenx Jobs | Formulate
Jobs
argenx
argenx Jobs
Belgium - Zwijnaarde
Biotechnology
argenx is a life sciences company focused on Antibody therapies.
77
open positions at argenx
View Full Profile
Filters:
Immunology ×
Business Leader, Rocky Plains (Rocky Mountains)
argenx
Posted 3w ago
United States - Field
$204K - $281K
Full-time
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Business Leader, Midwest (Midwest)
argenx
Posted 3w ago
United States - Field
$204K - $281K
Full-time
Business Leader, South Central (Mid South)
argenx
Posted 3w ago
United States - Field
$204K - $281K
Full-time
Business Leader, South Central (Gulf South)
argenx
Posted 3w ago
United States - Field
$204K - $281K
Full-time
Business Leader, Great Lakes (Ohio)
argenx
Posted 3w ago
United States - Field
$204K - $281K
Full-time
Business Leader, Northwest (Coastal CA)
argenx
Posted 3w ago
United States - Field
$204K - $281K
Full-time
Business Leader, Texas (South Texas)
argenx
Posted 3w ago
United States - Field
$204K - $281K
Full-time
Market Head, Northeast
argenx
Posted 3w ago
United States - Field
$236K - $325K
Full-time
Market Head, New York Metro
argenx
Posted 3w ago
United States - Field
$236K - $325K
Full-time
Market Head, Texas
argenx
Posted 3w ago
United States - Field
$236K - $325K
Full-time
Business Leader, Northeast (Upstate NY & Southern NE)
argenx
Posted 3w ago
United States - Field
$204K - $281K
Full-time
Business Leader, Midwest (Chicago Metro)
argenx
Posted 3w ago
United States - Field
$204K - $281K
Full-time
Business Leader, New York Metro (New York)
argenx
Posted 3w ago
United States - Field
$204K - $281K
Full-time
Business Leader, New York Metro (Pennsylvania)
argenx
Posted 3w ago
United States - Field
$204K - $281K
Full-time
Business Leader, Southwest (Southwest)
argenx
Posted 3w ago
United States - Field
$204K - $281K
Full-time
Market Head, Great Lakes
argenx
Posted 3w ago
United States - Field
$236K - $325K
Full-time
Market Head, Florida & Puerto Rico
argenx
Posted 3w ago
United States - Field
$236K - $325K
Full-time
Business Leader, Rocky Plains (Great Plains)
argenx
Posted 3w ago
United States - Field
$204K - $281K
Full-time
Business Leader, Texas (North Texas)
argenx
Posted 3w ago
United States - Field
$204K - $281K
Full-time
Market Head, Southeast
argenx
Posted 3w ago
United States - Field
$236K - $325K
Full-time
Previous
1
2
3
Company Overview
Active Jobs
84
Pipeline Programs
88
Drug Products
2
Clinical Trials
98
View Full Company Profile
Therapeutic Areas
Neurology
Immunology
Oncology
Links
Company Website
Careers Page
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
4
Next
Hematology
Rare Diseases